Healthcare
Solana Company(HSDT)
Live Price
Offline$1.62
+1.25% today
1Y Change
-90.71%
Window
Jun 25, 2025 β Jun 23, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +1057.1%
- EPS Growth
- +57.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solana Company (HSDT) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $1.62 and down 90.7% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of +1057.1%, EPS growth of +57.3%, a dividend yield of 0.0%. What stands out right now is revenue +1057.1%, EPS +57.3%, free cash flow -454.9% with operating margin -351.0% and ROIC -7.0%. Valuation already assumes a fairly strong business story at price/sales 13.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HSDT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1057.1% vs +7.6% peer median
Operating Margin
Below sector median
-351.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1057.1% and EPS at +57.3%, with operating margin around -351.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | β | +3.3% | +11.2% | -40.9% |
2026 Mar 30, 2026 | +116.0% | -7.0% | -1.6% | +11.8% |
2025 Nov 18, 2025 | +34.9% | -6.0% | -10.3% | -28.2% |
Benchmark Edge
HSDT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HSDT
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HSDT Max Drawdown
-94.74%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HSDT and SPY.
Company Overview
Solana Company
NASDAQ Capital Market
Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brainβs ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.
- Leadership
- Dane Carl Andreeff
- IPO Date
- Jun 27, 2014
- Employees
- 21
- Street Address
- 642 Newtown Yardley Road
- Mailing
- Newtown, PA, 18940
- Region
- Newtown, PA, US
- Reporting Currency
- USD
- Investor Line
- 215 944 6100
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 13.7
- Price/Book
- 0.1
Growth
- Revenue
- +1057.1%
- EPS
- +57.3%
- Free Cash Flow
- -454.9%
Profitability
- Gross Margin
- 91.7%
- Operating Margin
- -351.0%
- Net Margin
- -679.6%
- ROE
- -105.0%
- ROIC
- -7.0%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 10.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.